Insightful synthesis and discussion by Prof Kevin Harrington The Royal Marsden Cancer Charity The Royal Marsden NHS Foundation Trust comparing and contrasting KN630 and C-POST 💡time to start adj IO 🚨effect of ENI? #ASCO25 Shlomo Koyfman Neil D. Gross, MD, FACS

What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72

👋🚨NIVOPOSTOP GORTEC #ASCO25 ‼️adj nivo x1 ➡️concurrent nivo-CRT➡️ nivo improved DFS (mostly LRC). Waiting for OS results.

🚨 #ASCO25 plenary NIVOPOSTOP: 1st DFS win in 20+ yrs for resected high-risk LA-SCCHN ➡️ n=666, NIVO + CRT vs CRT alone 🎉 3-yr DFS: 63.1% vs 52.5% 💥HR 0.76 (p=0.034) ⚠️ mild Gr4 AEs ⬆️ w/ NIVO (13.1% vs 5.6%) ✅ New adjuvant IO standard emerging? #hnscc #Immunotherapy #RadOnc

2nd Plenary #ASCO25: #NIVOPOSTOP Ph III, adj Nivolumab w/ ChemoXRT in high risk squamous cell head & neck ca after surgery. - 3yr DFS: 63.1% vs 52.5% (HR: 0.76). Benefit in all subgroups including CPS/PDL1 - Similar AEs in both arms - Is benefit driven by locations control?

5th Plenary #ASCO25: #MATTERHORN Ph III, Durvalumab + FLOT—>✂️—>Durva vs NeoAdj FLOT in resectable GEJ/Gastric Ca. - 2yr EFS 67% vs 59% (HR: 0.71). Improvement regardless of PDL1 - 2yr OS 76% vs 70%. mOS NR - Rate of✂️& number of FLOT similar in both arms - D-FLOT new SoC!

🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…

Landmark OS data from #CheckMate816 just dropped in NEJM! 🫁 Neoadjuvant #Nivolumab + chemo in resectable #NSCLC delivers: ✅ 5-yr OS: 65.4% vs 55.0% ✅ HR: 0.72 (p=0.048) ✅ Lung cancer–specific survival HR: 0.65 ✅ OS with pCR: 95.3% ✅ ctDNA clearers: 75%+ OS 📌 No lung

~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/

It seems we are in a bit of a data quagmire. I often get asked how to choose between neoadjuvant versus perioperative immunotherapy and right now there aren’t many great answers, but for what it’s worth, here’s my general perspective… #ASCO25

Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa…

How to select pts with HCC for various local therapies? RFA ,MWA , TACE , SIRT , SBRT . Useful for clinical decision-making. Taken from #asco25 ASCO Do u agree ? Yakup Ergün Dr. Nina Niu Sanford Jeff Ryckman OncoAlert Kate Sears

Honored to be recognized by Atlanta Magazine as one of this year’s Top Doctors in Radiation Oncology! Grateful to my colleagues, mentors & patients who inspire me daily #radonc …antamagazine.mydigitalpublication.com/atlanta-magazi…

I learned this week that SABR-COMET patient #1 recently passed away, more than 12 years after enrollment, with no recurrence since his original SABR. We initially treated him for a left adrenal met. It’s an interesting story… ⬇️⬇️⬇️

#radonc sciencedirect.com/science/articl… Thanks to Dr. Chhabra, and team for spearheading this important discussion. And thanks to the usual suspects that speak up for the health of the field and young doctors. Mudit Chowdhary, MD, Chirag Shah, James Bates

Our Editorial on the Advanced Practice Radiation Therapist Model is in IJROBP - The Red Journal We outline why the APRT role—as it is currently formulated—raises structural, clinical & operational concerns for the United States radiation oncology landscape sciencedirect.com/science/articl… #radonc

🚨ACCORD Trial🚨 Resected Extrahepatic CCA or Gallbladder CA 🔍Randomized Adjuvant CRT + Camrelizumab vs Observation 🔥Whopping improvement in OS and RFS with CRT + ICI with persistent separate at tail of the curve!!! tinyurl.com/64yc3uum JAMA Oncology

Chad Tang, MD & I happy to report: ph2 basket EXTEND-OP trial has enrolled and randomized 150 patients in the last year since opening: - 7 histology-specific baskets - Oligoprogressive dz randomized to: ☢ Local Tx + continued same-line systemic, versus 💊Switching systemic Tx

🫁 Intrathoracic relapse after PACIFIC-regimen for LA-NSCLC remains a major therapeutic challenge. 🧪 In the AUSTRAL trial, led by Matthias Guckenberger & Andrea R. Filippi, we target this unmet need by combining RT (reRT and/or metastatis-directed SBRT) + durvalumab + ceralasertib

The Man Who Never Got a Nobel, But Gave the World Methotrexate — A story of forgotten genius, cancer, arthritis, psoriasis… and hope. 💊💔🧬